CRIS vs CRVS

Curis, Inc. vs Corvus Pharmaceuticals, Inc. — Valuation Comparison 2026

CRIS

Biotechnology
Curis, Inc.
Quality
5.0
out of 10
Value Trap
39
LOW
Price
$0.52
Last close
Models
9/13
Active
VS

CRVS

Biotechnology
Corvus Pharmaceuticals, Inc.
Quality
4.6
out of 10
Value Trap
18
SAFE
Price
$12.50
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CRIS Fair ValueCRIS Upside CRVS Fair ValueCRVS Upside
Bayesian DCF Intrinsic $0.25 -51.6% $3.61 -71.1%
First Chicago Scenario $0.34 -35.8% $18.64 +48.3%
ML-RIV Intrinsic $0.35 -40.6% $0.51 -96.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRIS vs CRVS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRIS vs CRVS — Which Stock Is More Undervalued?

CRIS scores higher with a 5.0/10 quality rating vs CRVS's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Curis, Inc. (CRIS) and Corvus Pharmaceuticals, Inc. (CRVS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRIS currently trades at $0.52 with a QOC of 5.0/10, while CRVS trades at $12.50 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).